Pfizer, Inc. (NYSE:PFE) is reporting third quarter earnings results on Tuesday 27th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.71 per share.
For the full year, analysts predict revenues of $ 49335.90 million, while looking forward to income of $ 2.90 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 48,600.00 million ~ $ 50,600.00 million, where as bottomline are predicted in a range of $ 2.85 ~ $ 2.95 per share
Click Here For More Historical Outlooks Of Pfizer, Inc.
Previous Quarter Performance
Pfizer, Inc. unwinded income for the second quarter of $ 0.78 per share, from the revenue of $ 11,801.00 million. The quarterly earnings decreased 2.50 percent while revenues decreased 11.03 percent compared with the same quarter last year.
Street analysts expected Pfizer, Inc. to report income of $ 0.66 per share on revenue of $ 11552.50 million for the second quarter. The bottom line results beat street analysts by $ 0.12 or 18.18 percent, at the same time, top line results outshined analysts by $ 248.50 million or 2.15 percent.
Stock Performance
Shares of Pfizer, Inc. traded up $ 0.75 or 2.00 percent on Friday, reaching $ 38.18 with volume of 25.23 million shares. Pfizer, Inc. has traded high as $ 38.29 and has cracked $ 37.65 on the downward trend
According to the previous trading day, closing price of $ 38.18, representing a 34.25 % increase from the 52 week low of $ 27.88 and a 8.64 % decrease over the 52 week high of $ 40.97.
The company has a market capital of $ 212.16 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 29th September 2020, initiated by Berenberg Bank at Hold rating, with $ 38.00 target price.
Conference Call
Pfizer, Inc. will be hosting a conference call at 10:00 AM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.pfizer.com
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
